Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy

The objective of this study was to evaluate the safety and efficacy of clobazam in children with refractory focal epilepsy. We investigated 100 consecutive patients concerning etiology of epilepsy, previously used antiepileptic drugs, seizure frequency and adverse events. Clobazam was introduced as add-on therapy in patients with previous failure of at least two monotherapies. Mean age was eight years-old and 39 patients were girls. Clobazam mean dosage was 23.6 mg/day. Mean use of clobazam was 18.6 months. Twenty-two patients had adverse events. Twenty-six patients became seizure-free, 11 had an improvement of >75% and in 58 there was no modification in seizure frequency. Five patients had an increase in seizure frequency. Clobazam efficacy lasted for more than one year in 42% of the seizure-free patients. Clobazam seems to be safe and effective in the treatment of focal epilepsy in childhood and should be considered in patients with refractory seizures.

Saved in:
Bibliographic Details
Main Authors: Silveira,Mariana Ribeiro Marcondes da, Montenegro,Maria Augusta, Franzon,Renata Cristina, Guerreiro,Carlos A.M., Guerreiro,Marilisa M.
Format: Digital revista
Language:English
Published: Academia Brasileira de Neurologia - ABNEURO 2006
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2006000500001
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0004-282X2006000500001
record_format ojs
spelling oai:scielo:S0004-282X20060005000012006-10-11Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsySilveira,Mariana Ribeiro Marcondes daMontenegro,Maria AugustaFranzon,Renata CristinaGuerreiro,Carlos A.M.Guerreiro,Marilisa M. clobazam focal epilepsy childhood The objective of this study was to evaluate the safety and efficacy of clobazam in children with refractory focal epilepsy. We investigated 100 consecutive patients concerning etiology of epilepsy, previously used antiepileptic drugs, seizure frequency and adverse events. Clobazam was introduced as add-on therapy in patients with previous failure of at least two monotherapies. Mean age was eight years-old and 39 patients were girls. Clobazam mean dosage was 23.6 mg/day. Mean use of clobazam was 18.6 months. Twenty-two patients had adverse events. Twenty-six patients became seizure-free, 11 had an improvement of >75% and in 58 there was no modification in seizure frequency. Five patients had an increase in seizure frequency. Clobazam efficacy lasted for more than one year in 42% of the seizure-free patients. Clobazam seems to be safe and effective in the treatment of focal epilepsy in childhood and should be considered in patients with refractory seizures.info:eu-repo/semantics/openAccessAcademia Brasileira de Neurologia - ABNEUROArquivos de Neuro-Psiquiatria v.64 n.3b 20062006-09-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2006000500001en10.1590/S0004-282X2006000500001
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Silveira,Mariana Ribeiro Marcondes da
Montenegro,Maria Augusta
Franzon,Renata Cristina
Guerreiro,Carlos A.M.
Guerreiro,Marilisa M.
spellingShingle Silveira,Mariana Ribeiro Marcondes da
Montenegro,Maria Augusta
Franzon,Renata Cristina
Guerreiro,Carlos A.M.
Guerreiro,Marilisa M.
Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy
author_facet Silveira,Mariana Ribeiro Marcondes da
Montenegro,Maria Augusta
Franzon,Renata Cristina
Guerreiro,Carlos A.M.
Guerreiro,Marilisa M.
author_sort Silveira,Mariana Ribeiro Marcondes da
title Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy
title_short Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy
title_full Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy
title_fullStr Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy
title_full_unstemmed Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy
title_sort effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy
description The objective of this study was to evaluate the safety and efficacy of clobazam in children with refractory focal epilepsy. We investigated 100 consecutive patients concerning etiology of epilepsy, previously used antiepileptic drugs, seizure frequency and adverse events. Clobazam was introduced as add-on therapy in patients with previous failure of at least two monotherapies. Mean age was eight years-old and 39 patients were girls. Clobazam mean dosage was 23.6 mg/day. Mean use of clobazam was 18.6 months. Twenty-two patients had adverse events. Twenty-six patients became seizure-free, 11 had an improvement of >75% and in 58 there was no modification in seizure frequency. Five patients had an increase in seizure frequency. Clobazam efficacy lasted for more than one year in 42% of the seizure-free patients. Clobazam seems to be safe and effective in the treatment of focal epilepsy in childhood and should be considered in patients with refractory seizures.
publisher Academia Brasileira de Neurologia - ABNEURO
publishDate 2006
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2006000500001
work_keys_str_mv AT silveiramarianaribeiromarcondesda effectivenessofclobazamasaddontherapyinchildrenwithrefractoryfocalepilepsy
AT montenegromariaaugusta effectivenessofclobazamasaddontherapyinchildrenwithrefractoryfocalepilepsy
AT franzonrenatacristina effectivenessofclobazamasaddontherapyinchildrenwithrefractoryfocalepilepsy
AT guerreirocarlosam effectivenessofclobazamasaddontherapyinchildrenwithrefractoryfocalepilepsy
AT guerreiromarilisam effectivenessofclobazamasaddontherapyinchildrenwithrefractoryfocalepilepsy
_version_ 1756374347531943937